SNY - First Wave BioPharma To Acquire ImmunogenX To Bolster Gastrointestinal-Focused Pipeline | Benzinga
First Wave BioPharma Inc (NASDAQ: FWBI) has signed a non-binding term sheet to acquire ImmunogenX in an all-stock transaction with the combined company focused on advancing a pipeline for gastrointestinal (GI) diseases.
James Sapirstein will continue to serve as Chairman, President, and CEO of First Wave BioPharma, with Jack Syage, CEO and co-founder of ImmunogenX, assuming the role of Chief Medical Officer.
The transaction is expected to close in the first half of 2024. The financial terms of the transaction were not disclosed.
First Wave BioPharma anticipates a significant non-dilutive financial investment from a strategic global pharmaceutical company for commercial rights ...